Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Joanna Säleby, Habib Bouzina, Salaheldin Ahmed, Jakob Lundgren, Göran Rådegran. Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019

Member's Comments

No comment yet.

Related content which might interest you: Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 PDGF and Src tyrosine kinases in pulmonary arterial smooth muscle cells: Effects of dasatinib and nilotinib on pulmonary vascular remodeling Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017 Year: 2017 Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries Source: Eur Respir J 2013; 41: 85-95 Year: 2013 Tyrosine kinase inhibition of human pulmonary fibroblast migration Source: Eur Respir J 2005; 26: Suppl. 49, 101s Year: 2005 Expression of the MET receptor kinase is a potential functional marker of Idiopathic pulmonary fibrosis Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis Year: 2017 The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1426-1433 Year: 2015 Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020 Year: 2020 Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Looking to the future: a new decade of pulmonary arterial hypertension therapy Source: Eur Respir Rev 2011; 20: 262-269 Year: 2011 NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008 Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed Source: Eur Respir J 2013; 41: 3-4 Year: 2013 Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010